Stifel Financial’s VYNE Therapeutics VYNE Stock Holding History

Stifel Financial’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-189	Closed	-$38K	–	2962
2020 Q1	$38K	Buy	+189	New	+$59.3K	﹤0.01%	2680

Other funds holding VYNE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stifel Financial's VYNE Position: Q2 2020 in Review

Stifel Financial sold out of VYNE Therapeutics (VYNE) in Q2 2020, closing a stake of 189 shares — an estimated $38K sold.

Stifel Financial first reported a position in VYNE in Q1 2020 and held it in 1 quarter. The position peaked at $38K in Q1 2020. 106 funds tracked by Wall St. Rank hold VYNE as of Q2 2020.

Stifel Financial reported no remaining VYNE Therapeutics position as of Q2 2020 after selling out during the quarter.
Stifel Financial sold 189 VYNE Therapeutics shares in Q2 2020, an estimated $38K.
Stifel Financial first reported a position in VYNE Therapeutics in Q1 2020 and held it in 1 quarter.
Stifel Financial's VYNE Therapeutics position peaked at $38K in Q1 2020.
106 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2020.

Based on Stifel Financial's 13F filing for Q2 2020, filed 14 Aug 2020.